CCL4 Protein

Catalog No. ABIN7668467

This Recombinant CCL4 protein is expressed in Escherichia coli (E. coli).

Quick Overview for CCL4 Protein (ABIN7668467)

Target: CCL4 (Chemokine (C-C Motif) Ligand 4 (CCL4))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Cell Culture (CC)

Purity: > 98 %

Product Details

Purpose: Recombinant Human CCL4 protein(His Tag)

Sequence: Ala 24-Asn 92

Sterility: 0.2 μm filtered

Endotoxin Level: < 0.1 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Measure by its ability to chemoattract BaF3 cells transfected with human CCR5.The ED₅₀ for this effect is <10 ng/mL.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from sterile 50 mM Tris, 150 mM NaCl, pH 8.5.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Expiry Date: 12 months

Target Details

Target: CCL4 (Chemokine (C-C Motif) Ligand 4 (CCL4))

Alternative Name: CCL4

Background: CCL4 (C-C chemokine ligand 4), is a macrophage inflammatory protein with a chief effect in inflammation and immune-regulation, and was documented in cancer progression by promoting instability in the tumor environment. The inflammatory chemokine (C-C motif) ligand 4 (CCL4) plays an important role in the pathogenesis and progression of cancer. In particular, higher serum CCL4 levels in patients with oral squamous cell carcinoma (OSCC) are associated with a more advanced stage of disease. CCL4 may be a new molecular therapeutic target for inhibition of lymphangiogenesis and metastasis in OSCC. CCL3 and CCL4 loci may be marker SNPs for risk of HCV treatment outcome. CCL4 can enhance the recruitment of preosteoclasts to bone in the early stage, and the reduction of CCR5 promotes osteoclastogenesis when RANKL is prevalent.,ACT-2,MIP-1b: Macrophage Inflammatory Protein-1β

Molecular Weight:

calculated_mw: 7.8 kDa

observed_mw: 11 kDa

UniProt: P13236